Citigroup Inc. Grows Position in Sanofi (NASDAQ:SNY)

Citigroup Inc. grew its holdings in shares of Sanofi (NASDAQ:SNY) by 2.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 631,672 shares of the company’s stock after acquiring an additional 15,348 shares during the quarter. Citigroup Inc.’s holdings in Sanofi were worth $36,403,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. POM Investment Strategies LLC purchased a new stake in Sanofi during the second quarter valued at about $25,000. Northwest Investment Counselors LLC bought a new position in shares of Sanofi during the 3rd quarter valued at about $29,000. Concord Wealth Partners raised its holdings in shares of Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after buying an additional 363 shares in the last quarter. Arrow Financial Corp bought a new stake in Sanofi in the 2nd quarter worth approximately $35,000. Finally, Fortitude Family Office LLC boosted its stake in Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after buying an additional 659 shares in the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SNY. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Stock Up 0.6 %

Shares of NASDAQ SNY opened at $48.28 on Monday. The company has a market cap of $122.53 billion, a price-to-earnings ratio of 24.63, a PEG ratio of 1.22 and a beta of 0.61. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The firm’s fifty day moving average is $53.70 and its 200 day moving average is $52.18. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. The firm had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.55 earnings per share. On average, equities research analysts expect that Sanofi will post 4.29 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.